Clinical Trials (PDQ®)
|Phase II||Biomarker/Laboratory analysis, Treatment||Active||18 and over||NCI, Other||E3311|
NCI-2013-00814, ECOG-E3311, U10CA180820, U10CA021115, NCT01898494
This randomized phase II trial studies how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery.
Further Study Information
I. Accrual, risk distribution, and surgical quality will be used to determine the feasibility of a prospective multi-institutional study of transoral surgery for HPV positive (+) oropharynx cancer followed by risk-adjusted adjuvant therapy.
II. To assess the oncologic efficacy following transoral resection and adjuvant therapy in patients determined to be at "intermediate risk" after surgical excision, the 2-year progression free survival (PFS) rate will be examined.
I. To estimate the patient distribution with various histologic risk features. II. To assess and compare early and late toxicities associated with transoral surgery (TOS) and the different doses of adjuvant postoperative radiotherapy (PORT).
III. To evaluate swallowing function before and after TOS and risk-adjusted adjuvant therapy.
IV. To evaluate quality of life (QOL), swallowing perception and performance, voice outcomes, and head and neck symptoms.
I. To correlate tumor TP53 mutation and other associated mutation profile with pathologic findings, with PFS and other outcome parameters in patients with resectable HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) after the above treatments.
II. To evaluate radiation resistance markers, including excision repair cross complementing 1 (ERCC1) single nucleotide polymorphism and protein expression, and correlate them with treatment efficacy.
III. To investigate the usefulness of biomarkers in predicting progression-free survival and biomarkers, including tumor ERCC1, epidermal growth factor receptor (EGFR), plasma cytokine/chemokines, cellular immunity to HPV, and oral HPV deoxyribonucleic acid (DNA).
OUTLINE: Patients are classified by risk status (low risk, intermediate risk, or high risk) and assigned to the appropriate treatment group. Patients classified as intermediate risk are randomized to 1 or 2 treatment arms.
ARM A (low risk): Patients undergo transoral surgical resection of the oropharyngeal tumor.
ARM B (intermediate risk): Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo low-dose intensity modulated radiation therapy (IMRT) once daily (QD) five days a week for 5 weeks.
ARM C (intermediate risk): Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6 weeks.
ARM D (high risk): Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6-7 weeks. Patients also receive cisplatin intravenously (IV) over 60 minutes or carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.
- REGISTRATION TO SURGERY (ARM S)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Patients must have newly diagnosed, histologically or cytologically confirmed squamous cell carcinoma or undifferentiated carcinoma of the oropharynx; patients must have been determined to have resectable oropharyngeal disease; patients with primary tumor or nodal metastasis fixed to the carotid artery, skull base or cervical spine are not eligible
- Patients must have American Joint Committee on Cancer (AJCC) TNM tumor stage III, IV a, or IV b (with no evidence of distant metastases) as determined by imaging studies (performed < 4 weeks prior to pre-registration) and complete head and neck exam; the following imaging is required: computed tomography (CT) scan with IV contrast or magnetic resonance imaging (MRI)
- Patients must have biopsy-proven cyclin-dependent kinase inhibitor 2A (p16)+ oropharynx cancer; the histologic evidence of invasive squamous cell carcinoma may have been obtained from the primary tumor or metastatic lymph node; it is required that patients have nodal stage N1-N2b confirmed by clinical or radiographic methods (clinically N0 patients are not eligible)
- Carcinoma of the oropharynx associated with HPV as determined by p16 protein expression using immunohistochemistry (IHC) performed by a Clinical Laboratory Improvement Amendments (CLIA) approved laboratory; using p16 antibody obtained from Roche mtm laboratories AG (CINtec, clone E6H4) is recommended
- No prior radiation above the clavicles
- Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer
- Patients with the following within the last 6 months prior to pre-registration must be evaluated by a cardiologist and/or neurologist prior to entry into the study
- Patients must not have evidence of extensive or "matted/fixed" pathologic adenopathy on preoperative imaging
- Absolute neutrophil count >= 1,500/mm^3
- Platelets >= 100,000/mm^3
- Total bilirubin =< the upper limit of normal (ULN)
- Calculated creatinine clearance must be > 60 ml/min using the Cockcroft-Gault formula
- Women must not be pregnant or breast-feeding due to the teratogenicity of chemotherapy; all females of childbearing potential must have a blood test or urine study within 2 weeks prior to registration to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: has not undergone a hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- Patient must not have an intercurrent illness likely to interfere with protocol therapy or prevent surgical resection
- Patients must not have uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled hypertension within 30 days prior to pre-registration
- REGISTRATION/RANDOMIZATION TO STEP 2 - ARMS A, B, C AND D AND REGISTRATION TO STEP 3
- Histopathologic assessment of surgical pathology must include examination for perineural invasion (PNI) and lymphovascular invasion (LVI) and reported as absent or present; the absence or presence of extracapsular extension (ECE) requires gross and microscopic assessment and is defined to be:
- Absent (negative or nodal metastasis with smooth/rounded leading edge confined to thickened capsule/pseudocapsule),
- Present - minimal (tumor extends =< 1 mm beyond the lymph node capsule), or
- Present - extensive (gross, tumor extends > 1 mm beyond the lymph node capsule (includes soft tissue metastasis)
- Patients must have ECOG performance status 0 or 1
- Patient must be registered/randomized within 5-7 weeks following surgery
- Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception
Trial Lead Organizations/Sponsors
Eastern Cooperative Oncology GroupNational Cancer Institute
|Robert Ferris||Principal Investigator|
|Mayo Clinic Scottsdale|
|Michael L Hinni||Ph: 507-538-7623|
|Jonsson Comprehensive Cancer Center at UCLA|
|Abie H Mendelsohn||Ph: 888-798-0719|
|Stanford Cancer Center|
|Floyd C Holsinger||Ph: 650-498-7061|
|Porter Adventist Hospital|
|Keren Sturtz||Ph: 888-785-6789|
|University of Miami Sylvester Comprehensive Cancer Center - Miami|
|Giovana R Thomas||Ph: 866-574-5124|
|Florida Hospital Cancer Institute at Florida Hospital Orlando|
|Lee M. Zehngebot||Ph: 407-303-5623|
|University of Kentucky Chandler Medical Center|
|Thomas J Gal||Ph: 859-257-3379|
|Greater Baltimore Medical Center Cancer Center|
|Marshall A. Levine||Ph: 443-849-3706|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Jeremy D Richmon||Ph: 410-955-8804|
|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute|
|Tom Thomas||Ph: 617-724-5200|
|Josephine Ford Cancer Center at Henry Ford Hospital|
|Robert Anthony Chapman||Ph: 313-916-1784|
|St. John's Regional Health Center|
|Jay W Carlson||Ph: 800-821-7532|
|Methodist Estabrook Cancer Center|
|Russell B. Smith||Ph: 402-354-5144|
|Cleveland Clinic Taussig Cancer Center|
|David J Adelstein||Ph: 866-223-8100|
|Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center|
|Enver Ozer||Ph: 866-627-7616|
|Providence Cancer Center at Providence Portland Medical Center|
|Alison K Conlin||Ph: 503-215-6412|
|PinnacleHealth Regional Cancer Center at Polyclinic Hospital|
|Brij M Sood||Ph: 717-724-6765|
|Fox Chase Cancer Center - Philadelphia|
|Miriam N Lango||Ph: 215-728-4790|
|UPMC Cancer Centers|
|Robert L. Ferris||Ph: 412-647-8073|
|Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas|
|Baran D Sumer||Ph: 214-648-7097|
|Sentara Cancer Institute at Sentara CarePlex Hospital|
|Scott S Williams||Ph: 757-388-2406|
|Sentara Cancer Institute at Sentara Norfolk General Hospital|
|Scott S Williams||Ph: 757-388-2406|
|Froedtert Hospital and Medical College of Wisconsin|
|Stuart J. Wong||Ph: 414-805-4380|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01898494
ClinicalTrials.gov processed this data on September 16, 2014
Back to Top